Research programme: chimeric antigen receptor natural killer cell therapies - CytomX Therapeutics/MD Anderson Cancer Center

Drug Profile

Research programme: chimeric antigen receptor natural killer cell therapies - CytomX Therapeutics/MD Anderson Cancer Center

Alternative Names: ProCAR NK cell therapies; ProCAR-NK therapies

Latest Information Update: 10 Nov 2015

Price : $50

At a glance

  • Originator CytomX Therapeutics; University of Texas M. D. Anderson Cancer Center
  • Class Cell therapies; Immunoconjugates
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 05 Nov 2015 Early research in Cancer in USA (unspecified route)
  • 05 Nov 2015 CytomX and University of Texas M.D. Anderson Cancer Center agree to co-develop ProCAR NK cell therapies for cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top